[Neurological disorders in patients with hypoparathyroidism]

It was already known that hypoparathyroidism causes hypocalcemia and hyperphosphatemia. However, neurological manifestations in these patients remain poorly understood. Prior research has shown that electrolyte imbalances can affect brain function. But the link between hypoparathyroidism and specific neurological symptoms remains unclear. This gap motivated an investigation into the clinical patterns observed in affected individuals. No prior work had resolved whether seizures or calcifications are direct consequences of the condition. Researchers sought to clarify if neurological symptoms are due to metabolic factors or structural brain changes. This study aimed to bridge the knowledge gap by examining both clinical and biochemical data.

The aim was to evaluate clinical symptoms in hypoparathyroidism patients during normocalcemic periods. The specific problem was to determine if neurological symptoms arose from electrolyte imbalance or CNS lesions. The motivation was to distinguish between metabolic and structural causes of seizures. Researchers wanted to assess whether seizures could be managed through metabolic correction. They also sought to identify the prevalence of calcification in the CNS among these patients. The study aimed to clarify the relationship between calcification and neurological outcomes. Psychological and radiological assessments were included to evaluate cognitive effects. The goal was to inform treatment strategies and long-term monitoring protocols.

The study analyzed a cohort of 14 hypoparathyroidism patients across varying ages and disease durations. Clinical diagnosis was confirmed using history, physical exams, and biochemical tests. Neurological assessments included EEG and imaging to detect calcifications. Patients received calcium, magnesium, and vitamin D supplementation. Five patients were classified as true hypoparathyroidism, while nine had pseudo-hypoparathyroidism. Albright syndrome was diagnosed in eight of these nine. Neurological referrals were made for suspected epilepsy in five patients. Psychological testing was used to evaluate cognitive function in those with Albright syndrome.

Nine patients exhibited generalized seizures, with one experiencing absence attacks and balance issues. EEG findings in three patients supported generalized seizure activity. Calcium and vitamin D treatment led to seizure remission in five patients. Nine patients showed CNS calcifications detected via CT imaging. Five of eight Albright syndrome patients had mild to moderate mental retardation. No direct correlation was found between calcification location and neurological symptoms. Duration of hypoparathyroidism appeared linked to calcification severity. Metabolic correction reduced the need for anti-epileptic medications in some cases.

The authors propose that hypoparathyroidism can cause both functional and structural CNS changes. They suggest that correcting metabolic imbalances may reduce the need for anti-epileptic drugs. Calcification foci seem to correlate with disease duration rather than symptom severity. No direct link was found between calcification location and neurological abnormalities. The study emphasizes the need for long-term multidisciplinary care in these patients. Neurophysiological and imaging monitoring is recommended for those with CNS calcifications. Psychological assessments are necessary to track cognitive outcomes. The findings suggest that metabolic management is central to symptom control.